Literature DB >> 10802366

Locally advanced nasopharyngeal carcinoma: computed tomography findings, clinical evaluation, and treatment outcome.

M Altun1, N Tenekeci, E Kaytan, R Meral.   

Abstract

PURPOSE: We present our experience with computed tomography (CT) for delineating the extent of bone erosion in nasopharyngeal carcinoma (NPC) and propose that a new subdivision of Stage T4 disease be added to the staging criteria for cases of minimal bone disease, defined as erosion of the base of the sphenoid or the pterygoid without cranial nerve (CN) involvement. METHODS AND MATERIALS: We retrospectively reviewed the clinical findings, radiological findings, and treatment outcome in 64 patients with Stage T4 NPC, diagnosed according to the American Joint Committee on Cancer 4th edition criteria. The median follow-up was 34 months (range, 3-118 months). Statistical analyses were performed using the chi-square test, the Kaplan-Meier method, and the log-rank test.
RESULTS: Local control was achieved in 19 (46%) of 41 patients with CN deficits and 18 (78%) of 23 patients without CN deficits (p = 0.01). Overall 5-year survival with and without CN deficits was 25% and 58%, respectively (p = 0.01). When the 16 patients with minimal bone disease were compared to the remaining 48 patients, there were significant differences in local control rates (87% vs. 48%, p = 0. 006) and 5-year survival rates (68% vs. 28%, p = 0.008).
CONCLUSION: Among patients with Stage T4 NPC, a subgroup of patients with only minimal bone disease may have a more favorable prognosis, which may have a considerable bearing on our approach to this patient group.

Entities:  

Mesh:

Year:  2000        PMID: 10802366     DOI: 10.1016/s0360-3016(00)00426-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes?

Authors:  Tzu-Chen Yen; Yu-Chen Chang; Sheng-Chieh Chan; Joseph Tung-Chieh Chang; Ching-Han Hsu; Kun-Ju Lin; Wuu-Jyh Lin; Ying-Kai Fu; Shu-Hang Ng
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-30       Impact factor: 9.236

2.  T4-locally advanced nasopharyngeal carcinoma: prognostic influence of cranial nerve involvement in different radiotherapy techniques.

Authors:  Hsin-I Huang; Kee-Tak Chan; Chih-Hung Shu; Ching-Yin Ho
Journal:  ScientificWorldJournal       Date:  2013-12-09

3.  Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy.

Authors:  Yan-Ping Mao; Ling-Long Tang; Lei Chen; Ying Sun; Zhen-Yu Qi; Guan-Qun Zhou; Li-Zhi Liu; Li Li; Ai-Hua Lin; Jun Ma
Journal:  Chin J Cancer       Date:  2016-12-28

4.  CT-diagnosed severe skull base bone destruction predicts distant bone metastasis in early N-stage nasopharyngeal carcinoma.

Authors:  Wei Yi; Zhi-Gang Liu; Xian Li; Jiao Tang; Chang-Bin Jiang; Jing-Ye Hu; Zi-Wei Tu; Hui Wang; Dao-Li Niu; Yun-Fei Xia
Journal:  Onco Targets Ther       Date:  2016-11-14       Impact factor: 4.147

5.  Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.

Authors:  Xing-Li Yang; Yan Wang; Shao-Bo Liang; Sha-Sha He; Dan-Ming Chen; Hai-Yang Chen; Li-Xia Lu; Yong Chen
Journal:  BMC Cancer       Date:  2018-05-29       Impact factor: 4.430

6.  Diffusion-weighted MRI for predicting treatment response in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis.

Authors:  Min Kyoung Lee; Yangsean Choi; So-Lyung Jung
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

7.  Diagnostic value of diffusion-weighted magnetic resonance imaging for local and skull base recurrence of nasopharyngeal carcinoma after radiotherapy.

Authors:  Chen Wang; Lidong Liu; Shaolv Lai; Danke Su; Younan Liu; Guanqiao Jin; Xuna Zhu; Ningbin Luo
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.